Related Experiment Video

Updated: Aug 2, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

The Role of SGLT2 Inhibitors in Cardiovascular Management

Andy Wang1, Uzair Mahmood2, Subo Dey1

  • 1From the Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.

Cardiology in Review
|April 18, 2023
PubMed

Insights

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) now offer significant cardiovascular protection for patients with type 2 diabetes. These drugs reduce heart failure hospitalizations and cardiovascular mortality, becoming essential in cardiovascular therapy.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of death in type 2 diabetes patients.
  • Type 2 diabetes significantly increases the risk of heart failure and atherosclerotic CVD.
  • Limited therapeutic options previously existed to mitigate these cardiovascular risks.

Purpose of the Study:

  • To review the evolving role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in managing cardiovascular complications in type 2 diabetes.
  • To highlight the cardio-protective effects of SGLT2i beyond their glycemic control function.
  • To discuss the expanded application of SGLT2i across different heart failure phenotypes.

Main Methods:

  • Analysis of landmark clinical trials and recent research on SGLT2 inhibitors.
  • Evaluation of cardiovascular outcomes, including mortality and hospitalization rates.
  • Assessment of SGLT2i efficacy in patients with and without type 2 diabetes and varying ejection fractions.

Main Results:

  • SGLT2 inhibitors demonstrate significant cardio-protective effects.
  • These agents reduce cardiovascular mortality and heart failure hospitalizations.
  • Benefits are observed in patients with type 2 diabetes and also in those without, across reduced, mildly reduced, and preserved ejection fractions.

Conclusions:

  • SGLT2 inhibitors are now a cornerstone therapy for cardiovascular risk reduction in type 2 diabetes.
  • Their cardiovascular benefits extend to a broader patient population, including those with different types of heart failure.
  • SGLT2i represent a major therapeutic advance in cardiovascular medicine.

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K
In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
221
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
244
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
17
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
219
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.8K